Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Baseline Findings of PreventE4: A Double-Blind Placebo Controlled Clinical Trial Testing High Dose DHA in APOE4 Carriers before the Onset of Dementia

The Journal of Prevention of Alzheimer s Disease(2023)10.14283/jpad.2023.77Source: DataRank Database

Baseline Findings of PreventE4: A Double-Blind Placebo Controlled Clinical Trial Testing High Dose DHA in APOE4 Carriers before the Onset of Dementia is a research paper published in The Journal of Prevention of Alzheimer s Disease (2023). On theSindex it has a DataRank of 0.487. It has been cited 14 times, with 10 citing works in its 1-hop citation network.

N/A

0.487DataRank · unranked

Scored on demand from live citation data

Deposits data Open Access14 citations · 10 citing works in its network

Download PDF

Cite:

Linked data & code

nct

Data availability

Repositories this paper deposited data in (declared in PubMed).

ClinicalTrials.govNCT03613844

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (16 grants)Impact (FWCI 1.93)OA: goldTopics (41)IDs (PubMed, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 83%Citation Network 17%

Base Score Contribution

0.406

From this paper's citation signal

Citation Network Contribution

0.0804

From 5 citing papers with measurable signal

Learn more about DataRank methodology →

Top 5 citers driving the network score

Ranked by each citer's contribution to N(p) — log1p(C_q) divided by its reference count — out of 10 citers.

Therapeutic Challenges Derived from the Interaction Among Apolipoprotein E, Cholesterol, and Amyloid in Alzheimer’s Disease
International Journal of Molecular Sciences20245 citations50 referencesContributes 0.036
An inverse association of cerebral amyloid-β deposition and serum docosahexaenoic acid levels in cognitively normal older adults in Japan
Journal of Alzheimer s Disease20252 citations51 referencesContributes 0.022
Effects of DHA on cognitive dysfunction in aging and Alzheimer's disease: The mediating roles of ApoE
Progress in Lipid Research202342 citations181 referencesContributes 0.021
Proinflammatory factors inhibition and fish oil treatment: A promising therapy for neonatal seizures
IBRO Neuroscience Reports20241 citations56 referencesContributes 0.012
Targeting mitochondrial dysfunction in Alzheimer's disease: New findings and perspectives
Progress in Neuro-Psychopharmacology and Biological Psychiatry20253 citations345 referencesContributes 0.004

Authors (19)

Isabella C. Arellanes,A. Mazmanian,Luis de la Cruz‐Merino ORCID,José Antônio Baddini Martínez ORCID,Luis Contreras ORCID

Live enrichment

PubMed:37874103 OpenAlex:https://openalex.org/W4379802098

NIA NIH HHS

Grant: P30 AG066530

NIA NIH HHS

Grant: RF1 AG076124

NCATS NIH HHS

Grant: UL1 TR001855

NIA NIH HHS

Grant: R01 AG067063

NIA NIH HHS

Grant: R21 AG056518

NIA NIH HHS

Grant: R01 AG055770

NIA NIH HHS

Grant: R01 AG054434

NIA NIH HHS

Grant: RF1 AG078362

National Institutes of Health

Grant: 3UL1TR001855-06A1S1

Southern California Clinical and Translational Science Institute

National Institutes of Health

Grant: 3P30AG066530-04S1

Alzheimer Disease Research Center

National Institutes of Health

Grant: 1RF1AG076124-01A1

Brain cPLA2 as a mechanism for neuroinflammation in AD/ADRD with and without APOE4

National Institutes of Health

Grant: 1R01AG054434-01A1

The delivery of essential fatty acids to the Brain in Alzheimer's disease

National Institutes of Health

Grant: 1RF1AG078362-01

Effect of diabetes and AD pathology on brain imaging and cognition in Latino adults

National Institutes of Health

Grant: 5R01AG055770-02

Biomarkers of ABCA1 mediated functions in Alzheimers disease

National Institutes of Health

Grant: 5R01AG067063-04

ApoE, ABCA1 and endosomal dysregulation in AD

National Institutes of Health

Grant: 5R21AG056518-02

DHA brain delivery by APOE genotype

FWCI

1.93

Citation Percentile

0.8%

Citation Trend

2023

2024

2025

2026

goldLicense: cc-by

journalhttps://link.springer.com/content/pdf/10.14283/jpad.2023.77.pdf

HYBRIDhttps://link.springer.com/content/pdf/10.14283/jpad.2023.77.pdf

publisherhttps://link.springer.com/content/pdf/10.14283/jpad.2023.77.pdf

publisherhttps://api.elsevier.com/content/article/PII:S2274580724001717?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S2274580724001717?httpAccept=text/plain

Fields of Study

Fatty Acid Research and HealthEicosanoids and Hypertension PharmacologyNutritional Studies and DietMedicine03 medical and health sciences0302 clinical medicine

MeSH Terms

AgedAged, 80 and overAlzheimer DiseaseBrainDocosahexaenoic AcidsHumansMiddle AgedFatty Acids, Omega-3Apolipoprotein E4

Keywords

MedicineDementiaInternal medicinePlaceboDocosahexaenoic acidRandomized controlled trialPediatricsOncologyPolyunsaturated fatty acidDiseasePathologyFatty acidBiologyBrainLipidsapoEDHAAlzheimer’sAged, 80 and overDocosahexaenoic AcidsAlzheimer DiseaseApolipoprotein E4Fatty Acids, Omega-3HumansMiddle AgedAged

Sustainable Development Goals

SDG 0: Good health and well-being